Teckro funding will help the company to foster more clinical trials.
Teckro, a Limerick-based life sciences technology company, has bagged $25 million in Series C funding. The Teckro funding round was led by Northpond Ventures with participation from Founders Fund, Sands Capital Ventures, Bill Maris’ Section 32 venture fund, and Borealis Ventures.
With the Series C round of funding, the Irish company has accumulated around $43 million in the various round of fundings.
The clinical drug trials software clinical research company was kick-started in 2015 by Gary Hughes, Nigel Hughes, and Jacek Skrzypiec, who are also the founders of this company.
Gary Hughes, Teckro co-founder, and CEO said,
“The industry still relies heavily on paper, on working off retrospective data, and there is still an over-reliance on sending CRAs to busy research sites. This approach, together with the plethora of point solutions that get ‘bolted on’, only adds to the complexity and disjointed experience of research sites and patients.”
Right after closing the Series B funding in August 2017, the clinical drug trials software company has successfully catered to its users in more than 80 countries. With a strength of over 100 employees, Teckro has outreached its offices in places like Dublin, Ireland, Tennessee, and Limerick, Ireland, which is Teckro’s global headquarters.
With an aim to improve the conduct of clinical trials, Teckro is constantly working on its technology, thus deploying machine learning to improve the speed and accuracy of clinical trials. Taking it one step ahead, Teckro is bridging clinical drug trials to the organizations and people who are responsible for conducting trials.
In clear statement to TechCrunch, Hughes added,
“Our mission is to engage more physicians in clinical research. We believe increased participation by physicians (currently less than 3 percent globally) will provide greater access to patients, effectively making clinical research a treatment option for millions of patients with unmet medical needs. That requires a complete rethink of clinical trial operations, particularly the experience of research sites.”
He further added,
“It’s very much a ‘fix one thing’ approach, establishing new digital touch points that remove friction and provide busy research staff with instant access to critical trial information when it is needed most.”
The Teckro funding will help it to bring together the center of all site and patient interactions during the clinical trials, which will help save precious lives. The clinical research company tries to make it possible to provide relevant information to every active member of a clinical trial team.
From leading business houses to budding startups, everyone can bank on us for all their future insights.A look at our mighty stats is a proof enough of our intentions to drive emerging advancements in the mobile industry and reinventing digital media in every possible way JOIN US!